Billion-Dollar Hearts: Tenaya and Alnylam Join Forces to Target Genetic Causes of Cardiovascular Disease

Tenaya Therapeutics partners with Alnylam to discover new genetic targets for heart disease treatments, potentially earning up to $1.13 billion in milestones.